Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-AXEL: nab-paclitaxel versus docetaxel in previously treated advanced non-small-cell lung cancer
jRCTs071180037Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- May 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing nab-paclitaxel with docetaxel (2 arms). Primary endpoint: Overall survival. Started May 2015; status: completed.
02
Drugs
paclitaxeldocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs071180037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180037.